Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 2/2019

01-02-2019

Laparoscopic splenectomy for immune thrombocytopenia (ITP): long-term outcomes of a modern cohort

Authors: Luciano Tastaldi, David M. Krpata, Ajita S. Prabhu, Clayton C. Petro, Ivy N. Haskins, Arielle J. Perez, Hemasat Alkhatib, Iago Colturato, Chao Tu, Alan Lichtin, Michael J. Rosen, Steven Rosenblatt

Published in: Surgical Endoscopy | Issue 2/2019

Login to get access

Abstract

Background

The advent of newer second-line medical therapies (SLMT) for immune thrombocytopenia (ITP) has contributed to decreased rates of splenectomy, following a trend to avoid or delay surgery. We aimed to characterize the long-term outcomes of laparoscopic splenectomy (LS) for ITP at our institution, examining differences in LS efficiency when performed before or after SLMTs.

Methods

Adults with primary ITP who underwent LS between 2002 and 2016 were identified. Retrospective review of electronic medical records was supplemented with telephone interviews. Treatment response was defined according to current guidelines as complete responders (CR), responders (R), and non-responders (NR). Kaplan–Meier estimates assessed relapse-free rates, and predictors of long-term response were investigated using logistic regression.

Results

109 patients met inclusion criteria, from which 42% were treated with an SLMT before referral to LS. LS was completed in all cases, with no conversions or intraoperative complications. The perioperative morbidity was 7.3%, including 3 deep vein and 2 portal vein thrombosis, one reoperation for bleeding, and no mortalities. Splenectomy was initially effective in 99 patients (CR + R = 90.8%), and 10 patients were NR. At a median 62-month follow-up, 25 patients relapsed, resulting in a 68% CR + R rate. Proportion of CR + R was similar in patients who previously received SLMT and those who did not (61 vs. 76.7%, p = 0.08). CR + R patients were younger (45 vs. 53, p = 0.03), had higher preoperative platelet counts (36 vs. 19, p = 0.01), and experienced a higher increment in platelet counts during hospital stay (117 vs. 38, p < 0.001) as well as 30-days postoperatively (329 vs. 124, p < 0.001). Only a robust response in platelet count at 30-days postoperatively was independently associated with long-term response (OR 1.005, p = 0.006).

Conclusion

LS was curative in 68% of patients, with no statistically significant difference when performed before or after SLMTs. Outcomes remain challenging to predict preoperatively, with only a robust increase in platelet counts on short term being associated with long-term response.
Literature
1.
Cuker A, Cines DB, Neunert CE (2016) Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol 23:479–485CrossRefPubMed
2.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168–186CrossRef
3.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207CrossRef
4.
5.
Palandri F, Polverelli N, Sollazzo D, Romano M, Catani L, Cavo M, Vianelli N (2016) Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol 91:E267–E272CrossRefPubMed
6.
Rodeghiero F, Ruggeri M (2014) ITP and international guidelines: what do we know, what do we need? Presse Medicale 43:e61–e67CrossRef
7.
Zheng D, Huang CS, Huang SB, Zheng CX (2016) Laparoscopic splenectomy for primary immune thrombocytopenia: current status and challenges. World J Gastrointest Endosc 8:610–615CrossRefPubMedPubMedCentral
8.
Vecchio R, Marchese S, Intagliata E, Swehli E, Ferla F, Cacciola E (2013) Long-term results after splenectomy in adult idiopathic thrombocytopenic purpura: comparison between open and laparoscopic procedures. J Laparoendosc Adv Surg Tech A 23:192–198CrossRefPubMed
9.
Qu Y, Xu J, Jiao C, Cheng Z, Ren S (2014) Long-term outcomes of laparoscopic splenectomy versus open splenectomy for idiopathic thrombocytopenic purpura. Int Surg 99:286–290CrossRefPubMedPubMedCentral
10.
Ghanima W, Godeau B, Cines DB, Bussel JB (2012) How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 120:960–969CrossRefPubMed
11.
12.
Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, Cines DB, Cooper N, Godeau B, Greinacher A, Imbach P, Khellaf M, Klaassen RJ, Kuhne T, Liebman H, Mazzucconi MG, Newland A, Pabinger I, Tosetto A, Stasi R (2013) Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 121:2596–2606CrossRefPubMed
13.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393CrossRef
14.
Ahad S, Gonczy C, Advani V, Markwell S, Hassan I (2013) True benefit or selection bias: an analysis of laparoscopic versus open splenectomy from the ACS-NSQIP. Surg Endosc 27:1865–1871CrossRefPubMed
15.
Winslow ER, Brunt LM (2003) Perioperative outcomes of laparoscopic versus open splenectomy: a meta-analysis with an emphasis on complications. Surgery 134:647–653 (discussion 654–645)CrossRefPubMed
16.
Thai LH, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, Dumas G, Khellaf M, Bierling P, Michel M, Godeau B (2016) Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine 95:e5098CrossRefPubMedPubMedCentral
17.
18.
Buzele R, Barbier L, Sauvanet A, Fantin B (2016) Medical complications following splenectomy. J Visc Surg 153:277–286CrossRefPubMed
19.
Das SS, Bhattacharya S, Sen S (2013) Managing uncontrolled postsplenectomy reactive thrombocytosis in idiopathic thrombocytopenic purpura: role of thrombocytapheresis. Transfus Apheres Sci 49:171–173CrossRef
20.
Gonzalez-Porras JR, Escalante F, Pardal E, Sierra M, Garcia-Frade LJ, Redondo S, Arefi M, Aguilar C, Ortega F, de Cabo E, Fisac RM, Sanz O, Esteban C, Alberca I, Sanchez-Barba M, Santos MT, Fernandez A, Gonzalez-Lopez TJ (2013) Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 91:236–241CrossRefPubMed
21.
Wang M, Zhang M, Zhou J, Wu Z, Zeng K, Peng B, Niu T (2013) Predictive factors associated with long-term effects of laparoscopic splenectomy for chronic immune thrombocytopenia. Int J Hematol 97:610–616CrossRefPubMed
22.
Montalvo J, Velazquez D, Pantoja JP, Sierra M, Lopez-Karpovitch X, Herrera MF (2014) Laparoscopic splenectomy for primary immune thrombocytopenia: clinical outcome and prognostic factors. J Laparoendosc Adv Surg Tech A 24:466–470CrossRefPubMed
23.
Rijcken E, Mees ST, Bisping G, Krueger K, Bruewer M, Senninger N, Mennigen R (2014) Laparoscopic splenectomy for medically refractory immune thrombocytopenia (ITP): a retrospective cohort study on longtime response predicting factors based on consensus criteria. Int J Surg 12:1428–1433CrossRefPubMed
24.
Navez J, Hubert C, Gigot JF, Navez B, Lambert C, Jamar F, Danse E, Lannoy V, Jabbour N (2015) Does the site of platelet sequestration predict the response to splenectomy in adult patients with immune thrombocytopenic purpura? Platelets 26:573–576CrossRefPubMed
25.
Ahmed R, Devasia AJ, Viswabandya A, Lakshmi KM, Abraham A, Karl S, Mathai J, Jacob PM, Abraham D, Srivastava A, Mathews V, George B (2016) Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children: splenectomy in ITP. Ann Hematol 95:1429–1434CrossRefPubMed
26.
Xu T, Li N, Jin F, Wu K, Ye Z (2016) Predictive factors of idiopathic thrombocytopenic purpura and long-term survival in chinese adults undergoing laparoscopic splenectomy. Surg Laparosc Endosc Percutan Tech 26:397–400CrossRefPubMed
27.
Guan Y, Wang S, Xue F, Liu X, Zhang L, Li H, Yang R (2017) Long-term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol 98:235–241CrossRefPubMed
28.
Tada K, Ohta M, Saga K, Takayama H, Hirashita T, Endo Y, Uchida H, Iwashita Y, Inomata M (2018) Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surg Today 48:180–185CrossRefPubMed
29.
Liu EH, Dilip CK, Yeh TS, Wu JH, Jan YY, Chen MF (2013) Long-term relapse-free rurvival rate and predictive factors of idiopathic thrombocytopenic purpura in adults undergoing splenectomy. Biomed J 36:23–27CrossRefPubMed
30.
Kang CM, Lee JG, Kim KS, Choi JS, Lee WJ, Kim BR, Ko YW, Han JS, Min YH (2007) Long-term follow-up of laparoscopic splenectomy in patients with immune thrombocytopenic purpura. J Korean Med Sci 22:420–424CrossRefPubMedPubMedCentral
31.
Kim M, Park KM, Shin WY, Choe YM, Lee KY, Ahn SI (2017) Platelet count evolution as a predictor of outcome after splenectomy for immune thrombocytopenic purpura. Int J Hematol 105:433–439CrossRefPubMed
32.
Rodeghiero F, Ruggeri M (2008) Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol 83::91CrossRef
33.
Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB (2012) Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 119:5989–5995CrossRefPubMedPubMedCentral
34.
Grace RF, Neunert C (2016) Second-line therapies in immune thrombocytopenia. Hematol Am Soc Hematol Edu Program 2016:698–706CrossRef
35.
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373:641–648CrossRefPubMed
36.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377:393–402CrossRef
37.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371:395–403CrossRefPubMed
38.
Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S (2013) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 161:411–423CrossRefPubMed
39.
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A (2013) Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 121:537–545CrossRefPubMed
40.
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB (2017) Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 130:2527–2536CrossRefPubMed
Metadata
Title
Laparoscopic splenectomy for immune thrombocytopenia (ITP): long-term outcomes of a modern cohort
Authors
Luciano Tastaldi
David M. Krpata
Ajita S. Prabhu
Clayton C. Petro
Ivy N. Haskins
Arielle J. Perez
Hemasat Alkhatib
Iago Colturato
Chao Tu
Alan Lichtin
Michael J. Rosen
Steven Rosenblatt
Publication date
01-02-2019
Publisher
Springer US
Published in
Surgical Endoscopy / Issue 2/2019
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-018-6321-y

Other articles of this Issue 2/2019

Surgical Endoscopy 2/2019 Go to the issue

OriginalPaper

Robotic transanal minimally invasive surgery (TAMIS) with the newest robotic surgical platform: a multi-institutional North American experience

Review Article

A systematic review of the learning curve in robotic surgery: range and heterogeneity

OriginalPaper

Impact of 3D printing technology on the comprehension of surgical liver anatomy

OriginalPaper

Implementation of 3D printed superior mesenteric vascular models for surgical planning and/or navigation in right colectomy with extended D3 mesenterectomy: comparison of virtual and physical models to the anatomy found at surgery

New Technology

Colorectal endoscopic submucosal dissection using novel articulating devices: a comparative study in a live porcine model

OriginalPaper

Outcome of endoscopic small-bore naso-jejunal tube stenting in early postoperative jejunal limb obstruction after gastrectomy